Search
Imatinib
go.drugbank.com/drugs/DB00619ApprovedInvestigationalThe discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. … [L42220] Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
Asparaginase Escherichia coli
go.drugbank.com/drugs/DB00023ApprovedInvestigationalFor patients who develop hypersensitivity to _E. coli_-derived formulations of L-asparaginase, the use of PEGylated or non-PEGylated [DB08886] is recommended [A31999]. … Asparaginase from _E. coli_ has clinically shown to exhibit antitumor actions in models of leukaemias [A31996, A31997].
Synonyms: Asparaginase (E. coli), E. coli AsparaginaseVedolizumab
go.drugbank.com/drugs/DB09033ApprovedInvestigationalto its more favorable safety profile compared to its predecessor natalizumab, the first integrin receptor antagonist approved by the FDA. … [L48216] α4β7 integrin facilitates the interaction between lymphocytes and gut endothelial cells through the α4β7 integrin-MAdCAM1 interaction, leading to the mobilization of lymphocytes and thus contributing
Categories: Integrin Receptor AntagonistPeginterferon alfa-2a
go.drugbank.com/drugs/DB00008ApprovedInvestigationalActivation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. … -2a for the treatment of Hepatitis C [A19593].
Lodoxamide
go.drugbank.com/drugs/DB06794ApprovedLodoxamide is marketed under the brand name Alomide by Alcon. … Lodoxamide is a mast-cell stabilizer for topical administration into the eye.
Cefotaxime
go.drugbank.com/drugs/DB00493ApprovedInvestigationalIn most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).
Products: CLAFORAN 0.5 G IM/IV ENJEKSİYONLUK TOZ VE ÇÖZÜCÜ, CLAFORAN 2G/40 ML IM/IV ENJEKSİYONLUK TOZ VE ÇÖZÜCÜErenumab
go.drugbank.com/drugs/DB14039ApprovedInvestigationalCGRP receptor, which is believed to play a critical role in migraine [L2823]. … Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines
Categories: Calcitonin Gene-Related Peptide Receptor AntagonistsMacimorelin
go.drugbank.com/drugs/DB13074ApprovedMore specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels … Macimorelin is clinically useful since it displays good stability and oral bioavailability with comparable affinity to ghrelin receptor as its endogenous ligand.
Categories: Growth Hormone Secretagogue Receptor Agonist, Growth Hormone Secretagogue Receptor AgonistsFomivirsen
go.drugbank.com/drugs/DB06759ApprovedWithdrawnThe drug was withdrawn by the FDA because while there was a high unmet need for drugs to treat CMV when the drug was initially discovered and developed due to the CMV arising in people with AIDS, the development … Fomivirsen is marketed under the trade name Vitravene for intravitreal injection and was the first antisense drug to be approved by the Food and Drug Administration (FDA).
Hexocyclium
go.drugbank.com/drugs/DB06787ApprovedHexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment of gastric ulcer or diarrhea. … Proton pump inhibitors like [DB00338] and opiate anti-diarrheal agents like [DB00836] have largely replaced the use of anti-muscarinics in the treatment of gastric ulcers and diarrhea due to their more